Trial Profile

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients with AML, HR MDS, or Myeloid Blast Phase of CML

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Gilteritinib (Primary) ; Idarubicin (Primary) ; Midostaurin (Primary) ; Pegfilgrastim (Primary) ; Venetoclax (Primary) ; Granulocyte colony-stimulating factors
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

10 Dec 2024 Results (n=88) of subgroup analysis assessing Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine were presented at the 66th American Society of Hematology Annual Meeting and Exposition
24 Apr 2024 Planned number of patients changed from 458 to 508.
04 May 2023 Planned End Date changed from 31 May 2024 to 31 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com